Kennametal: Q4 Earnings Insights

Kennametal (NYSE:KMT) reported its Q4 earnings results on Monday, August 1, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Kennametal beat estimated earnings by 12.77%, reporting an EPS of $0.53 versus an estimate of $0.47.

byBenzinga Insights

August 1, 2022

1 minute read

Kennametal (NYSE:KMT) reported its Q4 earnings results on Monday, August 1, 2022 at 04:00 PM.

Here’s what investors need to know about the announcement.

Earnings

Kennametal beat estimated earnings by 12.77%, reporting an EPS of $0.53 versus an estimate of $0.47.

Revenue was up $14.04 million from the same period last year.

Past Earnings Performance

Last quarter the company beat on EPS by $0.05 which was followed by a 1.3% increase in the share price the next day.

Here’s a look at Kennametal’s past performance:

Quarter	Q3 2022	Q2 2022	Q1 2022	Q4 2021
EPS Estimate	0.42	0.38	0.38	0.40
EPS Actual	0.47	0.35	0.44	0.53
Revenue Estimate	510.61M	496.17M	487.19M	514.21M
Revenue Actual	512.26M	486.67M	483.51M	515.97M

To track all earnings releases for Kennametal visit their earnings calendar here.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Central Pacific Financial Q3 EPS $0.61 Beats $0.60 Estimate, Sales $55.40M Miss $55.41M Estimate

Central Pacific Financial (NYSE:CPF) reported quarterly earnings of $0.61 per share which beat the analyst consensus estimate of $0.60 by 1.67 percent. This is a 17.57 percent decrease over earnings of $0.74 per share

Regenxbio’s Earnings Outlook

Regenxbio (NASDAQ:RGNX) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors need to know before the announcement. Analysts estimate that Regenxbio will report an earnings per share (EPS) of $-1.46.

Novo Nordisk: Q3 Earnings Insights

Novo Nordisk (NYSE:NVO) reported its Q3 earnings results on Wednesday, November 2, 2022 at 01:30 AM. Here's what investors need to know about the announcement. Earnings Novo Nordisk beat estimated earnings by 3.61%, reporting an EPS of $0.86 versus an estimate of $0.83.